All Stories

  1. Aspirin Use and the Risk for Cardiovascular Disease by Lipoprotein(a) Levels: A Multi-Cohort Study
  2. Development and Validation of an Incident Hypertension Risk Prediction Model for Young Adults
  3. Development and Validation of Models to Estimate the Incident Risk of Cognitive Impairment and Atherosclerotic Cardiovascular Disease in Older Adults
  4. Hypertension Prevention and Healthy Life Expectancy in Black Adults: The Jackson Heart Study
  5. Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction
  6. Incident CHD and ischemic stroke associated with lipoprotein(a) by levels of Factor VIII and inflammation
  7. Association Between Triglycerides and Incident Cognitive Impairment in Black and White Adults in the Reasons for Geographic and Racial Differences in Stroke Study
  8. Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease
  9. Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction
  10. Higher Serum Urate Levels Are Associated With an Increased Risk for Sudden Cardiac Death
  11. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans
  12. Projections of incident atherosclerotic cardiovascular disease and incident type 2 diabetes across evolving statin treatment guidelines and recommendations: A modelling study
  13. Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria
  14. Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction
  15. The importance of using 24-hour and nighttime blood pressure for the identification of white coat hypertension: Data from the Jackson Heart Study
  16. Healthcare Utilization and Statin Re‐Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction
  17. Development of algorithms for identifying fatal cardiovascular disease in Medicare claims
  18. Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries
  19. Black-White Differences in Incident Fatal, Nonfatal, and Total Coronary Heart DiseaseClinical Perspective
  20. Blood Pressure, Antihypertensive Polypharmacy, Frailty, and Risk for Serious Fall Injuries Among Older Treated Adults With HypertensionNovelty and Significance
  21. Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg
  22. Primary Care Physician Perspectives on Barriers to Statin Treatment
  23. Race‐Sex Differences in Statin Use and Low‐Density Lipoprotein Cholesterol Control Among People With Diabetes Mellitus in the Reasons for Geographic and Racial Differences in Stroke Study
  24. Performance of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations by Social Deprivation Status
  25. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction
  26. Metabolic syndrome and masked hypertension among African Americans: The Jackson Heart Study
  27. Cardiovascular Health and Healthcare Utilization and Expenditures Among Medicare Beneficiaries: The REasons for Geographic And Racial Differences in Stroke (REGARDS) Study
  28. Modifiable Risk Factors Versus Age on Developing High Predicted Cardiovascular Disease Risk in Blacks
  29. Does Identification of Previously Undiagnosed Conditions Change Care-Seeking Behavior?
  30. Scientific Output on Transesophageal Echocardiography from Iberoamerican Countries
  31. Rates of hospitalization among African American and Caucasian American patients with Crohn's disease seen at a tertiary care center
  32. Stroke symptoms and risk for incident coronary heart disease in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study
  33. Linkage of a Population-Based Cohort With Primary Data Collection to Medicare Claims
  34. Development and Validation of the Framingham Steatosis Index to Identify Persons With Hepatic Steatosis
  35. Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data
  36. Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups: Age <50 Years, Diabetes Mellitus, or a History of Stroke
  37. Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study
  38. Association of Reduced eGFR and Albuminuria with Serious Fall Injuries among Older Adults
  39. Zolpidem use and motor vehicle collisions in older drivers
  40. Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels
  41. Healthy lifestyle factors and incident heart disease and mortality in candidates for primary prevention with statin therapy
  42. Resistencia antimicrobiana de Salmonella spp aislada de alimentos de origen animal para consumo humano
  43. Generalizability of SPRINT Results to the U.S. Adult Population
  44. Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use
  45. The role of cystatin-C in the confirmation of reduced glomerular filtration rate among the oldest old
  46. Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies
  47. Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality
  48. Beat-to-Beat Heart Rate and Blood Pressure Variability and Hypertensive Disease in Pregnancy
  49. Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels
  50. Disparities in Cardiovascular Research Output and Citations From 52 African Countries: A Time-Trend, Bibliometric Analysis (1999-2008)
  51. Systolic blood pressure levels and coronary heart disease, stroke, heart failure, and falls among adults 65 years and older taking antihypertensive medication
  52. Impact of Metabolic Syndrome on the Hospitalization Rate of Crohn's Disease Patients Seen at a Tertiary Care Center: A Retrospective Cohort Study
  53. Cross-Cultural Adaptation of a Text Message-Based Program for Smoking Cessation in Buenos Aires, Argentina
  54. Perfect Storm: Concurrent Stress and Depressive Symptoms Increase Risk of Myocardial Infarction or Death
  55. Contrasting Cholesterol Management Guidelines for Adults with CKD
  56. Factors involved in the paradox of reverse epidemiology
  57. Validation of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations
  58. Cardiovascular Research Publications from Latin America between 1999 and 2008. A Bibliometric Study
  59. Global Cardiovascular Research Output, Citations, and Collaborations: A Time-Trend, Bibliometric Analysis (1999–2008)
  60. Costo-Efectividad de la Proteína C Reactiva, Procalcitonina y Escala de Rochester: Tres Estrategias Diagnosticas para la Identificación de Infección Bacteriana Severa en Lactantes Febriles sin Foco
  61. No differences in short-term morbidity and mortality after robot-assisted laparoscopic versus laparoscopic resection for colonic cancer: a case–control study of 263 patients
  62. Correspondence Re: “Laparoscopic treatment of advanced colonic cancer: a case-matched control with open surgery by Vignali et al”
  63. A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries
  64. Therapy of Chagas Disease: Implications for Levels of Prevention
  65. Development and Validation of a Microsimulation Economic Model to Evaluate the Disease Burden Associated with Smoking and the Cost-Effectiveness of Tobacco Control Interventions in Latin America
  66. Estimation and Comparison of EQ-5D Health States' Utility Weights for Pneumoccocal and Human Papillomavirus Diseases in Argentina, Chile, and the United Kingdom
  67. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina
  68. Economic evaluations on cardiovascular preventive interventions in Argentina
  69. Estimación de la carga de las enfermedades cardiovasculares atribuible a factores de riesgo modificables en Argentina
  70. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries
  71. Strategies for improving the quality of health care in maternal and child health in low- and middle-income countries: an overview of systematic reviews
  72. Ezetimibe for primary hypercholesterolemia